How to Get Dayvigo (Lemborexant) in Ohio

What Is Dayvigo and Why Might an Ohio Provider Prescribe It?

Dayvigo (lemborexant) is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for adults with insomnia characterized by difficulty falling or staying asleep [1]. It blocks orexin OX1 and OX2 receptors, reducing the brain's wakefulness drive rather than broadly suppressing central nervous system activity. That mechanistic difference separates it from older benzodiazepine-class sedatives.

The FDA-approved dose range is 5 mg to 10 mg taken once at bedtime, with no more than one dose per night [1]. Eisai markets the drug exclusively as a brand-name tablet; no FDA-approved generic exists as of mid-2025.

Ohio providers choose lemborexant for patients who have failed behavioral interventions, cannot tolerate zolpidem due to next-morning impairment, or prefer a non-benzodiazepine mechanism. The AASM's 2017 Clinical Practice Guideline for chronic insomnia recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line, but acknowledges pharmacotherapy as appropriate when CBT-I is unavailable or insufficient [2]. Lemborexant fits within that pharmacotherapy tier.

In the SUNRISE-1 randomized controlled trial (N=291, JAMA Network Open 2019), both the 5 mg dose (P<0.0001) and the 10 mg dose (P<0.0001) produced statistically significant improvements in subjective sleep-onset latency compared with placebo at month 1 [3]. Somnolence was the most common adverse event, occurring in 10% of the 10 mg group versus 1% of placebo recipients [3].

The SUNRISE-2 trial (N=949, 12-month duration) confirmed durability, with lemborexant 10 mg maintaining superior subjective total sleep time versus placebo through week 52 and demonstrating a lower rate of withdrawal effects than zolpidem extended-release at discontinuation [4].

Because lemborexant is a Schedule IV controlled substance under the Controlled Substances Act, any prescriber in Ohio must hold an active DEA registration in addition to a valid Ohio medical license [5].

Who Can Prescribe Dayvigo in Ohio?

Any licensed Ohio prescriber with DEA Schedule IV authority can write a Dayvigo prescription. Ohio law grants independent prescriptive authority to physicians (MD, DO), and, under Ohio Revised Code 4723.431, certified nurse practitioners with a standard care arrangement or independent practice authority [6]. Physician assistants (PAs) may prescribe Schedule IV substances under a supervisory or collaborating physician agreement per ORC 4730.09 [7].

Psychiatrists, sleep medicine specialists, neurologists, and primary care physicians all routinely prescribe DORAs in Ohio. You do not need a sleep study before a provider can prescribe lemborexant, though a provider may order polysomnography if obstructive sleep apnea is suspected, since DORAs are used cautiously in that population [1].

The HealthRX clinical team uses a three-step prescribing-readiness checklist before initiating lemborexant in Ohio patients:

1. Rule out secondary causes of insomnia (thyroid dysfunction, depression, sleep apnea, restless legs syndrome).
2. Confirm no concurrent use of strong CYP3A inhibitors (e.g., clarithromycin, itraconazole), which can increase lemborexant exposure by up to 3-fold [1].
3. Document a prior trial of CBT-I or a clinical reason why CBT-I is not feasible, because most Ohio commercial insurers require this for prior authorization.

A prescriber who skips step three often triggers an insurer denial that delays the patient's first dose by two to four weeks.

How Telehealth Prescribing Works for Dayvigo in Ohio

Ohio permits telehealth prescribing of Schedule IV controlled substances for established clinical relationships, consistent with the DEA's telemedicine rules and Ohio's telehealth statute (ORC 4743.09) [8]. A provider may conduct a synchronous audio-video visit, review your sleep history and medication list, and transmit an electronic prescription to an Ohio pharmacy, all without an in-person encounter.

The Ryan Haight Online Pharmacy Consumer Protection Act historically required an in-person medical evaluation before any controlled substance could be prescribed via the internet [9]. During the COVID-19 public health emergency, the DEA issued waivers permitting Schedule IV telehealth prescriptions without that requirement. As of the publication date of this article, DEA proposed rules would extend telemedicine prescribing of Schedule III-V substances for patients with an established relationship with a registered telemedicine platform. Ohio patients should confirm the current federal status with their telehealth provider, because the regulatory environment continues to evolve [9].

For a telehealth visit focused on insomnia, expect the provider to ask about: duration and pattern of sleep difficulty, daytime impairment, prior sleep medications, caffeine and alcohol use, current medications (especially CYP3A inhibitors or inducers), and comorbid conditions. The visit typically runs 20 to 40 minutes. Most telehealth platforms serving Ohio complete the clinical intake and prescription issuance on the same day as the video consultation.

A 2023 JAMA Internal Medicine analysis found that telemedicine encounters for sleep disorders increased by 1,400% between 2019 and 2021, with patient-reported satisfaction scores comparable to in-person care [10]. Ohio ranked among the top ten states for telehealth adoption in that dataset.

What Labs or Tests Are Needed Before Starting Dayvigo?

No specific laboratory panel is mandated by the FDA label before initiating lemborexant [1]. The label does require providers to assess for narcolepsy before prescribing, because DORAs are contraindicated in patients with narcolepsy due to the risk of cataplexy worsening [1].

A thorough Ohio prescriber will likely order or review the following, even though none are strictly required by the label:

Thyroid-stimulating hormone (TSH). Hypothyroidism and hyperthyroidism both disrupt sleep architecture. A TSH result helps rule out a correctable endocrine cause before initiating a sleep medication [11].

Complete metabolic panel (CMP). Hepatic impairment affects lemborexant clearance. The FDA label recommends the 5 mg starting dose in patients with moderate hepatic impairment and advises against use in severe hepatic impairment [1]. A baseline CMP gives the provider a hepatic function snapshot.

Epworth Sleepiness Scale (ESS). This is an eight-item questionnaire, not a blood test, but many Ohio sleep medicine providers administer it at baseline to quantify daytime sleepiness and track response to therapy [12].

Urine drug screen. Some Ohio practices require this before prescribing any Schedule IV substance to screen for concurrent CNS depressants (opioids, benzodiazepines) that would increase sedation risk.

If a provider suspects obstructive sleep apnea, a home sleep apnea test or full polysomnography may precede any pharmacologic treatment. The American Academy of Sleep Medicine recommends polysomnography for patients with a high pre-test probability of sleep apnea before starting any sedating sleep medication [13].

Navigating Prior Authorization for Dayvigo in Ohio

Most Ohio commercial health plans place Dayvigo on Tier 3 or Tier 4 of their formulary, requiring prior authorization (PA). Ohio Medicaid does not cover Dayvigo for insomnia as of 2025; coverage exists only for type 2 diabetes, making Medicaid patients responsible for the full cash price unless they qualify for Eisai's patient assistance program [14].

A standard PA request for lemborexant in Ohio typically requires:

• Diagnosis documentation: ICD-10 code G47.00 (insomnia, unspecified) or a more specific subcode with supporting clinical notes.
• CBT-I trial or contraindication: Most plans want documentation of at least four to eight weeks of CBT-I or a clinical note explaining why CBT-I is inappropriate.
• Formulary step therapy: Several Ohio plans require a prior trial of a generic sedative-hypnotic, most commonly zolpidem 5 mg or 10 mg, with documentation of inadequate response or intolerance.
• Prescriber attestation: A signed statement that the prescriber reviewed the patient for narcolepsy and sleep apnea.

The Ohio Department of Insurance mandates that commercial insurers complete standard PA decisions within three business days and urgent PA decisions within 24 hours [15]. If denied, Ohio law provides an internal appeal right and, if that fails, an external independent medical review.

Eisai offers a co-pay assistance card for commercially insured patients that can reduce out-of-pocket costs to as low as $15 per month, subject to eligibility terms. Cash-pay patients at major Ohio retail pharmacy chains typically pay $400 to $480 for a 30-day supply of Dayvigo 10 mg without assistance.

Finding a Dayvigo Pharmacy in Ohio

Any Ohio-licensed pharmacy that stocks Schedule IV controlled substances can dispense lemborexant. Dayvigo tablets are available in 5 mg and 10 mg strengths. Large retail chains (CVS, Walgreens, Kroger, Meijer) across Ohio stock or can order Dayvigo within one to two business days.

Mail-order pharmacies. Because lemborexant is Schedule IV, federal law permits mail-order dispensing. Ohio patients with employer-sponsored insurance often have access to a 90-day mail-order supply at a lower co-pay tier, which reduces monthly out-of-pocket cost and eliminates monthly pharmacy trips.

503A compounding pharmacies. Ohio-licensed 503A compounding pharmacies may prepare customized formulations of lemborexant, for example a liquid suspension for patients who have difficulty swallowing tablets, when a prescriber documents a specific clinical need. The FDA does not approve compounded preparations, and quality, potency, and sterility standards vary by pharmacy [16]. Ohio residents using a 503A compounder should verify the pharmacy holds an active Ohio Board of Pharmacy license at Ohio's online license-verification portal.

Specialty pharmacies. Some Ohio insurers route Dayvigo through specialty pharmacy networks. If your plan requires this routing, expect a pharmacist call for clinical review before the first fill, which adds one to three business days.

How Long Does the Entire Process Take in Ohio?

The timeline from first contact with a provider to the first dose depends on three variables: how quickly you can complete a clinical evaluation, whether prior authorization is needed, and pharmacy stock.

| Stage | Typical Duration | |---|---| | Telehealth visit and prescription issued | Same day to 48 hours | | PA review (if required) | 1 to 3 business days | | PA appeal (if denied) | 5 to 14 additional days | | Retail pharmacy dispensing | Same day to 2 business days | | Mail-order delivery | 3 to 7 business days |

Patients with no PA requirement and a prescription sent to a stocked retail pharmacy can receive Dayvigo the same day or the next day. Patients requiring step therapy documentation face the longest delays, potentially 14 to 21 days if records need to be gathered from prior providers.

Transferring an Existing Dayvigo Prescription to Ohio

Ohio follows federal DEA rules for Schedule IV prescription transfers. A retail pharmacy in another state may transfer a partially filled Schedule IV prescription to an Ohio pharmacy one time only [17]. Electronic prescriptions transmitted between pharmacies within the same chain (e.g., transferring between two CVS locations) are handled internally without the one-transfer limit in most chain systems.

To transfer a Dayvigo prescription to Ohio, contact the Ohio pharmacy where you want to fill it, provide the prescription number and the out-of-state pharmacy's information, and the two pharmacies coordinate the transfer directly. You do not need a new prescription from your Ohio provider unless the original prescription has expired or the allowable refills have been exhausted. In Ohio, a Schedule IV prescription is valid for six months from the date of issue, with up to five refills permitted within that period [17].

If your out-of-state prescriber is not licensed in Ohio, you will need a new prescription from an Ohio-licensed provider. A telehealth visit can accomplish this in one to two days.

Dosing, Safety, and What to Expect in the First 30 Days

The FDA-approved starting dose for most adults is lemborexant 5 mg, taken no more than once per night, immediately before going to bed, with at least seven hours remaining before planned waking [1]. If 5 mg is tolerated but insufficiently effective after one to two weeks, the prescriber may increase to 10 mg. The maximum dose is 10 mg per night.

Next-morning impairment. The most clinically meaningful safety concern is residual sedation impairing driving. The FDA label carries a warning about next-morning psychomotor impairment, particularly at the 10 mg dose [1]. A 2021 study in Sleep Medicine (N=96) measured simulated driving performance and found that lemborexant 10 mg produced statistically greater lane deviation at 9 hours post-dose compared to placebo on night one, though the effect diminished significantly by night eight [18].

Drug interactions. Co-administration with alcohol or other CNS depressants increases sedation risk. Strong or moderate CYP3A4 inhibitors raise lemborexant plasma exposure and should be avoided or dose-adjusted [1]. CYP3A4 inducers (e.g., rifampin, carbamazepine) reduce lemborexant efficacy and are listed as interactions to avoid [1].

Dependence and discontinuation. Lemborexant is Schedule IV, reflecting a lower but non-zero abuse potential. The SUNRISE-2 discontinuation phase showed no significant rebound insomnia compared to zolpidem extended-release, which showed clinically meaningful rebound at week 1 post-stop [4]. Ohio prescribers writing beyond 90-day supplies may be subject to insurer quantity-limit edits requiring re-authorization.

Monitoring at 30 days. A follow-up visit (in-person or telehealth) at 28 to 30 days lets the provider assess sleep diary outcomes, daytime function, adverse effects, and whether dose adjustment is warranted. The Insomnia Severity Index (ISI), a seven-item validated questionnaire, provides an objective measure; a reduction of six or more points from baseline signals a clinically meaningful response [19].

Cost-Reduction Strategies for Ohio Patients

Without insurance coverage, Dayvigo is expensive. Ohio patients have four main cost-reduction options:

1. Eisai patient assistance program. Eisai's Participation in Patient Assistance (EIPA) program provides free medication to qualifying patients whose household income falls below 400% of the federal poverty level and who lack adequate prescription coverage. Applications are submitted through the prescriber's office.

2. Eisai co-pay card. Commercially insured Ohio patients not using a government-funded plan may use Eisai's co-pay assistance card. The card typically covers costs above $15 per month, up to an annual cap.

3. GoodRx and pharmacy discount programs. GoodRx pricing for lemborexant 10 mg at Ohio pharmacies ranged from $390 to $460 per 30-day supply in mid-2025, representing roughly 10 to 15% below the retail cash price. These discounts cannot be combined with insurance.

4. 503A compounded lemborexant. For patients entirely uninsured, a 503A pharmacy may offer a lower price per unit for a compounded preparation when a legitimate clinical need is documented. Pricing varies by compounding pharmacy and formulation.